Healtinib 12.5mg Capsule
Product Info
Prescription required | Yes |
Marketer | Torrent Pharmaceuticals Ltd |
Active Ingredient | Sunitinib (12.5mg) |
Storage | Store below 30°C |
Chemical Class | Indole and Pyrrole Derivative |
Habit Forming | No |
Therapeutic Class | ANTI NEOPLASTICS |
Action Class | Tyrosine kinase inhibitors |
User Rating | 4.3 |
User Reviews | 711 |
FAQ
Healtinib 12.5mg Capsule Reviews
Healtinib 12.5mg can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Common side effects of this medicine include weakness, diarrhea, nausea, vomiting, taste change, and decreased appetite. The doctor may advise for regular monitoring of blood pressure and thyroid gland function while taking this medicine. It may decrease blood sugar levels. In fact, the levels can decrease to the extent that the patient may faint. So, if you are diabetic then it is important to check your blood sugar levels regularly. Additionally, you should also consult the doctor if the dose of anti-diabetic medicines needs to be adjusted.
Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or bleeding disorder. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
How Healtinib 12.5mg Capsule Works
How to Use Healtinib 12.5mg Capsule
Benefits of Healtinib 12.5mg Capsule
- In Treatment of Gastrointestinal stromal tumour: A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs most commonly in the stomach or small intestine. The tumors develop into the specialized cells called interstitial cells of Cajal (ICCs). Healtinib 12.5mg helps to kill the cancer cells and also stops their further growth and spread. Follow your doctor’s instructions carefully to get the most benefit.
- In Treatment of Kidney cancer: Healtinib 12.5mg is used to treat kidney cancer and its associated symptoms such as blood in the urine, unexplained low back pain or weight loss, fatigue, loss of appetite, etc. It stops cancer growth and prevents multiplication of cancer cells. This restricts the advancement of cancer to other unaffected regions. You need to follow your doctor’s instructions very carefully to recover.
Uses of Healtinib 12.5mg Capsule
- Treatment of Gastrointestinal stromal tumour
- Treatment of Kidney cancer
Healtinib 12.5mg Capsule Side Effects
Safety Tips
Quick Tips
- Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
- Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, confusion, problems with your eyesight, nausea or vomiting.
- It may affect wound healing time. Be careful while shaving, cutting fingernails or toenails, or using sharp objects.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
- Do not take this medicine if you are pregnant, planning to conceive or breastfeeding.
- Monitoring of thyroid gland function is required while taking this medicine. Inform your doctor if you notice symptoms of weight gain, dry skin, and hair.
- In case you need to undergo any surgical procedure, ensure to inform the doctor about your use of Healtinib 12.5mg.
References
- Sunitinib malate. Sandwich, Kent: Pfizer Limited; 2006 [revised Feb. 2019].
- Sunitinib malate [Prescribing Information]. New York, New York: Pfizer Inc.; 2021.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1304.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 955.
- Central Drugs Standard Control Organisation (CDSCO).
- Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 1740.